318 related articles for article (PubMed ID: 33310017)
21. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
22. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.
Yuan M; Liu H; Wu NC; Wilson IA
Biochem Biophys Res Commun; 2021 Jan; 538():192-203. PubMed ID: 33069360
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.
Zheng L; Ma Y; Chen M; Wu G; Yan C; Zhang XE
Biochem Biophys Res Commun; 2021 Nov; 579():69-75. PubMed ID: 34592572
[TBL] [Abstract][Full Text] [Related]
24. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin fragment F(ab')
Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
Qiang M; Ma P; Li Y; Liu H; Harding A; Min C; Wang F; Liu L; Yuan M; Ji Q; Tao P; Shi X; Li Z; Li T; Wang X; Zhang Y; Wu NC; Lee CD; Zhu X; Gilbert-Jaramillo J; Zhang C; Saxena A; Huang X; Wang H; James W; Dwek RA; Wilson IA; Yang G; Lerner RA
Adv Sci (Weinh); 2022 Jan; 9(1):e2102181. PubMed ID: 34716683
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
[TBL] [Abstract][Full Text] [Related]
28. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
[TBL] [Abstract][Full Text] [Related]
29. Effect of An 84-bp Deletion of the Receptor-Binding Domain on the ACE2 Binding Affinity of the SARS-CoV-2 Spike Protein: An In Silico Analysis.
Kemenesi G; Tóth GE; Bajusz D; Keserű GM; Terhes G; Burián K; Zeghbib S; Somogyi BA; Jakab F
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572725
[TBL] [Abstract][Full Text] [Related]
30. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
Mehdipour AR; Hummer G
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
[TBL] [Abstract][Full Text] [Related]
31. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
[TBL] [Abstract][Full Text] [Related]
32. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
Front Immunol; 2021; 12():730766. PubMed ID: 34630410
[TBL] [Abstract][Full Text] [Related]
33. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.
Lin S; Chen Z; Zhang X; Wen A; Yuan X; Yu C; Yang J; He B; Cao Y; Lu G
Signal Transduct Target Ther; 2022 Feb; 7(1):56. PubMed ID: 35190526
[No Abstract] [Full Text] [Related]
34. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice.
Huang K; Zhang Y; Hui X; Zhao Y; Gong W; Wang T; Zhang S; Yang Y; Deng F; Zhang Q; Chen X; Yang Y; Sun X; Chen H; Tao YJ; Zou Z; Jin M
EBioMedicine; 2021 May; 67():103381. PubMed ID: 33993052
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
36. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
[TBL] [Abstract][Full Text] [Related]
37. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
38. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
39. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
Glasgow A; Glasgow J; Limonta D; Solomon P; Lui I; Zhang Y; Nix MA; Rettko NJ; Zha S; Yamin R; Kao K; Rosenberg OS; Ravetch JV; Wiita AP; Leung KK; Lim SA; Zhou XX; Hobman TC; Kortemme T; Wells JA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28046-28055. PubMed ID: 33093202
[TBL] [Abstract][Full Text] [Related]
40. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
